Unknown PHASE1 INTERVENTIONAL 1-arm NCT02131688

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Interventions Mitoxantrone Hydrochloride Liposome

Updated 4 times since 2017 Last updated: May 4, 2014 Started: May 31, 2013 Primary completion: Aug 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02131688, this PHASE1 trial focuses on Malignant Lymphoma and remains ongoing. Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., it has been updated 4 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China